0

Close
 
Upcoming Allied Market Research
2023
Arthropod Born Viral Infections Market

Arthropod Born Viral Infections Market: Global Opportunity Analysis and Industry Forecast, 2023-2030 Market

LS : Therapeutics
Report Code: A10480
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Arthropod Born Viral Infections Market

Request Now !

Arboviral disease is a general term used to describe infections caused by a group of viruses spread among humans by the bite of infected arthropods (insects) such as mosquitoes and ticks; for instance, California encephalitis, Chikungunya, dengue, Eastern equine encephalitis, Powassan, St. Louis encephalitis, West Nile, Yellow Fever, and Zika. Other diseases spread by the bite of infected arthropods that are not viral infections, such as Lyme disease, which is a bacterial infection, and babesiosis, which is a parasitic infection, are not arboviral. The onset of these infections is witnessed during warm weather months, when mosquitoes and ticks are active.. Young children and the elderly appear to be most susceptible to arboviral infection. People who travel to or reside in areas where certain arboviruses are commonly found are at increased risk of acquiring an arboviral infection.

COVID-19 scenario analysis

Pharmaceutical and biotechnological companies together with governments around the globe are working to combat the COVID-19 outbreak, from supporting the development of vaccines to scheduling medicines supply chain challenges. Around 115 vaccine candidates and other 155 molecules are in the R&D pipeline. Furthermore, the commonly used drugs, such as hydroxychloroquine, have observed huge boost in demand for the management of COVID-19. In addition, increase has been experienced in the demand for COVID-19 management drugs, which is expected to offer potential opportunity for manufacturers of drugs, as many developed countries are short of these drugs. Owing to the growing demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is anticipated to witness a substantial growth in the next few years.

Top impacting factors: market scenario analysis, trends, drivers, and impact analysis

The major factor affecting the arthropod born viral infections market include increase in the prevalence of several arbovirus disorders. This would help the market to gain traction over the next few years. Furthermore, increase in healthcare expenditure is anticipated to boost the market in the coming years. However, lack of awareness regarding the infectious diseases may hinder the growth of the arthropod born viral infections market over the forecast period.

Rise in incidence of encephalitis

The steep increase in the number of incidences of encephalitis would help the arthropod born viral infections market to flourish in the forecast period. According to the estimates given by the World Health Organization in 2019, Japanese encephalitis virus (JEV) is one of the major causes of viral encephalitis in various countries of Asia, and is estimated to cause 68,000 clinical cases every year. Furthermore, the fatality rate among those with encephalitis can be observed to be as high as 30%. In addition to this, there can be other side effects of the JEV, which include permanent neurologic or psychiatric sequelae. This may occur in about 30–50% of the patient population. Thus, growth in the patient population of encephalitis may propel the growth of the market in the coming years.

Surge in number of product launches for diagnostics of the disease

Increase in the number of molecular diagnostic techniques to identify the infection is anticipated to help the arthropod born viral infections market boost in the coming years. For instance, in October 2019, Co-Diagnostics, Inc. announced that the diagnostic method for the identification of the encephalitis virus will be ready in 2020. This is a Biotech company having a patented platform for the development of the molecular diagnostic tests. The test for eastern equine encephalitis (EEE) is stated to get ready in the next mosquito season, which is during 2020. Increase in R&D to develop diagnostic methods for the identification of potential encephalitis virus is expected to gain the attention of the majority of the civil population, and hence the awareness toward the encephalitis virus tends to increase. This is expected to help the market to gain traction in the next few years.

Key benefits of the report:

  • This study presents the analytical depiction of the global arthropod born viral infections industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global arthropod born viral infections market share.
  • The current market is quantitatively analyzed to highlight the global arthropod born viral infections market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the arthropod born viral infections market .
  • The report provides a detailed global arthropod-born viral infections market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the arthropod born viral infections market research report:

  • Which are the leading players active in the arthropod born viral infections market?
  • What are the current trends that will influence the arthropod born viral infections market in the next few years?
  • What are the driving factors, restraints, and opportunities of the arthropod born viral infections market ?
  • What are the projections for the future that would help in tasking further strategic steps?

 Arthropod Born Viral Infections Market: Global Opportunity Analysis and Industry Forecast, 2020–2027 Report Highlights

Aspects Details
By Test Type
  • Cultural tests
  • Immunoassays
  • Molecular tests
  • Others
By End User
  • Hospitals
  • Research centers
  • Diagnostic centers
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Fluke Biomedical,, BioMed,, Acmas Technologie,, Diste., Copley Scientific,, Bio-Rad,, Ahlborn,, AESKU.GROUP,, Datrend System,, Agilent Technologies,
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: ARTHROPOD BORN VIRAL INFECTIONS MARKET, BY TEST TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Test Type

    • 4.2. Cultural Tests

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Immunoassays

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Molecular Tests

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Others

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: ARTHROPOD BORN VIRAL INFECTIONS MARKET, BY END USER

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By End User

    • 5.2. Hospitals

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Research Centers

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Diagnostic Centers

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Others

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: ARTHROPOD BORN VIRAL INFECTIONS MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Test Type

      • 6.2.3. Market Size and Forecast, By End User

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Arthropod Born Viral Infections Market

        • 6.2.5.1. Market Size and Forecast, By Test Type
        • 6.2.5.2. Market Size and Forecast, By End User

      • 6.2.6. Canada Arthropod Born Viral Infections Market

        • 6.2.6.1. Market Size and Forecast, By Test Type
        • 6.2.6.2. Market Size and Forecast, By End User

      • 6.2.7. Mexico Arthropod Born Viral Infections Market

        • 6.2.7.1. Market Size and Forecast, By Test Type
        • 6.2.7.2. Market Size and Forecast, By End User

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Test Type

      • 6.3.3. Market Size and Forecast, By End User

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Arthropod Born Viral Infections Market

        • 6.3.5.1. Market Size and Forecast, By Test Type
        • 6.3.5.2. Market Size and Forecast, By End User

      • 6.3.6. Germany Arthropod Born Viral Infections Market

        • 6.3.6.1. Market Size and Forecast, By Test Type
        • 6.3.6.2. Market Size and Forecast, By End User

      • 6.3.7. Italy Arthropod Born Viral Infections Market

        • 6.3.7.1. Market Size and Forecast, By Test Type
        • 6.3.7.2. Market Size and Forecast, By End User

      • 6.3.8. Spain Arthropod Born Viral Infections Market

        • 6.3.8.1. Market Size and Forecast, By Test Type
        • 6.3.8.2. Market Size and Forecast, By End User

      • 6.3.9. UK Arthropod Born Viral Infections Market

        • 6.3.9.1. Market Size and Forecast, By Test Type
        • 6.3.9.2. Market Size and Forecast, By End User

      • 6.3.10. Russia Arthropod Born Viral Infections Market

        • 6.3.10.1. Market Size and Forecast, By Test Type
        • 6.3.10.2. Market Size and Forecast, By End User

      • 6.3.11. Rest Of Europe Arthropod Born Viral Infections Market

        • 6.3.11.1. Market Size and Forecast, By Test Type
        • 6.3.11.2. Market Size and Forecast, By End User

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Test Type

      • 6.4.3. Market Size and Forecast, By End User

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Arthropod Born Viral Infections Market

        • 6.4.5.1. Market Size and Forecast, By Test Type
        • 6.4.5.2. Market Size and Forecast, By End User

      • 6.4.6. Japan Arthropod Born Viral Infections Market

        • 6.4.6.1. Market Size and Forecast, By Test Type
        • 6.4.6.2. Market Size and Forecast, By End User

      • 6.4.7. India Arthropod Born Viral Infections Market

        • 6.4.7.1. Market Size and Forecast, By Test Type
        • 6.4.7.2. Market Size and Forecast, By End User

      • 6.4.8. South Korea Arthropod Born Viral Infections Market

        • 6.4.8.1. Market Size and Forecast, By Test Type
        • 6.4.8.2. Market Size and Forecast, By End User

      • 6.4.9. Australia Arthropod Born Viral Infections Market

        • 6.4.9.1. Market Size and Forecast, By Test Type
        • 6.4.9.2. Market Size and Forecast, By End User

      • 6.4.10. Thailand Arthropod Born Viral Infections Market

        • 6.4.10.1. Market Size and Forecast, By Test Type
        • 6.4.10.2. Market Size and Forecast, By End User

      • 6.4.11. Malaysia Arthropod Born Viral Infections Market

        • 6.4.11.1. Market Size and Forecast, By Test Type
        • 6.4.11.2. Market Size and Forecast, By End User

      • 6.4.12. Indonesia Arthropod Born Viral Infections Market

        • 6.4.12.1. Market Size and Forecast, By Test Type
        • 6.4.12.2. Market Size and Forecast, By End User

      • 6.4.13. Rest of Asia Pacific Arthropod Born Viral Infections Market

        • 6.4.13.1. Market Size and Forecast, By Test Type
        • 6.4.13.2. Market Size and Forecast, By End User

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Test Type

      • 6.5.3. Market Size and Forecast, By End User

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Arthropod Born Viral Infections Market

        • 6.5.5.1. Market Size and Forecast, By Test Type
        • 6.5.5.2. Market Size and Forecast, By End User

      • 6.5.6. South Africa Arthropod Born Viral Infections Market

        • 6.5.6.1. Market Size and Forecast, By Test Type
        • 6.5.6.2. Market Size and Forecast, By End User

      • 6.5.7. Saudi Arabia Arthropod Born Viral Infections Market

        • 6.5.7.1. Market Size and Forecast, By Test Type
        • 6.5.7.2. Market Size and Forecast, By End User

      • 6.5.8. UAE Arthropod Born Viral Infections Market

        • 6.5.8.1. Market Size and Forecast, By Test Type
        • 6.5.8.2. Market Size and Forecast, By End User

      • 6.5.9. Argentina Arthropod Born Viral Infections Market

        • 6.5.9.1. Market Size and Forecast, By Test Type
        • 6.5.9.2. Market Size and Forecast, By End User

      • 6.5.10. Rest of LAMEA Arthropod Born Viral Infections Market

        • 6.5.10.1. Market Size and Forecast, By Test Type
        • 6.5.10.2. Market Size and Forecast, By End User

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Bio-Rad,

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Copley Scientific,

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Acmas Technologie,

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Fluke Biomedical,

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Datrend System,

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Agilent Technologies,

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Ahlborn,

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. AESKU.GROUP,

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. BioMed,

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Diste.

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL ARTHROPOD BORN VIRAL INFECTIONS MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR CULTURAL TESTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR IMMUNOASSAYS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR MOLECULAR TESTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL ARTHROPOD BORN VIRAL INFECTIONS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR RESEARCH CENTERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL ARTHROPOD BORN VIRAL INFECTIONS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. NORTH AMERICA ARTHROPOD BORN VIRAL INFECTIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 15. U.S. ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 16. U.S. ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 17. CANADA ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 18. CANADA ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 19. MEXICO ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 20. MEXICO ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 21. EUROPE ARTHROPOD BORN VIRAL INFECTIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 22. EUROPE ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 23. EUROPE ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 24. FRANCE ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 25. FRANCE ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 26. GERMANY ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 27. GERMANY ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 28. ITALY ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 29. ITALY ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 30. SPAIN ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 31. SPAIN ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 32. UK ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 33. UK ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 34. RUSSIA ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 35. RUSSIA ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 36. REST OF EUROPE ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 37. REST OF EUROPE ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 38. ASIA-PACIFIC ARTHROPOD BORN VIRAL INFECTIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 39. ASIA-PACIFIC ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 40. ASIA-PACIFIC ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 41. CHINA ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 42. CHINA ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 43. JAPAN ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 44. JAPAN ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 45. INDIA ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 46. INDIA ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 47. SOUTH KOREA ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 48. SOUTH KOREA ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 49. AUSTRALIA ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 50. AUSTRALIA ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 51. THAILAND ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 52. THAILAND ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 53. MALAYSIA ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 54. MALAYSIA ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 55. INDONESIA ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 56. INDONESIA ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 57. REST OF ASIA PACIFIC ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 58. REST OF ASIA PACIFIC ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 59. LAMEA ARTHROPOD BORN VIRAL INFECTIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 60. LAMEA ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 61. LAMEA ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 62. BRAZIL ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 63. BRAZIL ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 64. SOUTH AFRICA ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH AFRICA ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 66. SAUDI ARABIA ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 67. SAUDI ARABIA ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 68. UAE ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 69. UAE ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 70. ARGENTINA ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 71. ARGENTINA ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 72. REST OF LAMEA ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 73. REST OF LAMEA ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 74. BIO-RAD,: KEY EXECUTIVES
  • TABLE 75. BIO-RAD,: COMPANY SNAPSHOT
  • TABLE 76. BIO-RAD,: OPERATING SEGMENTS
  • TABLE 77. BIO-RAD,: PRODUCT PORTFOLIO
  • TABLE 78. BIO-RAD,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 79. COPLEY SCIENTIFIC,: KEY EXECUTIVES
  • TABLE 80. COPLEY SCIENTIFIC,: COMPANY SNAPSHOT
  • TABLE 81. COPLEY SCIENTIFIC,: OPERATING SEGMENTS
  • TABLE 82. COPLEY SCIENTIFIC,: PRODUCT PORTFOLIO
  • TABLE 83. COPLEY SCIENTIFIC,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 84. ACMAS TECHNOLOGIE,: KEY EXECUTIVES
  • TABLE 85. ACMAS TECHNOLOGIE,: COMPANY SNAPSHOT
  • TABLE 86. ACMAS TECHNOLOGIE,: OPERATING SEGMENTS
  • TABLE 87. ACMAS TECHNOLOGIE,: PRODUCT PORTFOLIO
  • TABLE 88. ACMAS TECHNOLOGIE,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 89. FLUKE BIOMEDICAL,: KEY EXECUTIVES
  • TABLE 90. FLUKE BIOMEDICAL,: COMPANY SNAPSHOT
  • TABLE 91. FLUKE BIOMEDICAL,: OPERATING SEGMENTS
  • TABLE 92. FLUKE BIOMEDICAL,: PRODUCT PORTFOLIO
  • TABLE 93. FLUKE BIOMEDICAL,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 94. DATREND SYSTEM,: KEY EXECUTIVES
  • TABLE 95. DATREND SYSTEM,: COMPANY SNAPSHOT
  • TABLE 96. DATREND SYSTEM,: OPERATING SEGMENTS
  • TABLE 97. DATREND SYSTEM,: PRODUCT PORTFOLIO
  • TABLE 98. DATREND SYSTEM,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 99. AGILENT TECHNOLOGIES,: KEY EXECUTIVES
  • TABLE 100. AGILENT TECHNOLOGIES,: COMPANY SNAPSHOT
  • TABLE 101. AGILENT TECHNOLOGIES,: OPERATING SEGMENTS
  • TABLE 102. AGILENT TECHNOLOGIES,: PRODUCT PORTFOLIO
  • TABLE 103. AGILENT TECHNOLOGIES,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 104. AHLBORN,: KEY EXECUTIVES
  • TABLE 105. AHLBORN,: COMPANY SNAPSHOT
  • TABLE 106. AHLBORN,: OPERATING SEGMENTS
  • TABLE 107. AHLBORN,: PRODUCT PORTFOLIO
  • TABLE 108. AHLBORN,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 109. AESKU.GROUP,: KEY EXECUTIVES
  • TABLE 110. AESKU.GROUP,: COMPANY SNAPSHOT
  • TABLE 111. AESKU.GROUP,: OPERATING SEGMENTS
  • TABLE 112. AESKU.GROUP,: PRODUCT PORTFOLIO
  • TABLE 113. AESKU.GROUP,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 114. BIOMED,: KEY EXECUTIVES
  • TABLE 115. BIOMED,: COMPANY SNAPSHOT
  • TABLE 116. BIOMED,: OPERATING SEGMENTS
  • TABLE 117. BIOMED,: PRODUCT PORTFOLIO
  • TABLE 118. BIOMED,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 119. DISTE.: KEY EXECUTIVES
  • TABLE 120. DISTE.: COMPANY SNAPSHOT
  • TABLE 121. DISTE.: OPERATING SEGMENTS
  • TABLE 122. DISTE.: PRODUCT PORTFOLIO
  • TABLE 123. DISTE.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTHROPOD BORN VIRAL INFECTIONS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL ARTHROPOD BORN VIRAL INFECTIONS MARKET
  • FIGURE 3. SEGMENTATION ARTHROPOD BORN VIRAL INFECTIONS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN ARTHROPOD BORN VIRAL INFECTIONS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALARTHROPOD BORN VIRAL INFECTIONS MARKET
  • FIGURE 11. ARTHROPOD BORN VIRAL INFECTIONS MARKET SEGMENTATION, BY BY TEST TYPE
  • FIGURE 12. ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR CULTURAL TESTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR MOLECULAR TESTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. ARTHROPOD BORN VIRAL INFECTIONS MARKET SEGMENTATION, BY BY END USER
  • FIGURE 17. ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR RESEARCH CENTERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 22. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 23. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 24. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 25. COMPETITIVE DASHBOARD
  • FIGURE 26. COMPETITIVE HEATMAP: ARTHROPOD BORN VIRAL INFECTIONS MARKET
  • FIGURE 27. Top player positioning, 2022
  • FIGURE 28. BIO-RAD,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 29. BIO-RAD,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 30. BIO-RAD,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 31. COPLEY SCIENTIFIC,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 32. COPLEY SCIENTIFIC,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 33. COPLEY SCIENTIFIC,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 34. ACMAS TECHNOLOGIE,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 35. ACMAS TECHNOLOGIE,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 36. ACMAS TECHNOLOGIE,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 37. FLUKE BIOMEDICAL,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 38. FLUKE BIOMEDICAL,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 39. FLUKE BIOMEDICAL,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 40. DATREND SYSTEM,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 41. DATREND SYSTEM,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 42. DATREND SYSTEM,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 43. AGILENT TECHNOLOGIES,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. AGILENT TECHNOLOGIES,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 45. AGILENT TECHNOLOGIES,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 46. AHLBORN,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. AHLBORN,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 48. AHLBORN,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 49. AESKU.GROUP,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 50. AESKU.GROUP,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 51. AESKU.GROUP,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 52. BIOMED,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. BIOMED,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 54. BIOMED,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 55. DISTE.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. DISTE.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 57. DISTE.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Arthropod Born Viral Infections Market

Start reading.
This Report and over 66,804+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers